Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Life Science Group Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is being handled by 1 distinct examiner, Gina Pronzati, within 1 distinct art unit. This indicates a very focused prosecution landscape where only one matter is currently active.
Gina Pronzati is the busiest examiner, responsible for 1 pending office action. This 1 pending office action represents the entire current workload for the company in the Biotechnology & Pharmaceuticals area. With only 1 distinct art unit and 1 distinct examiner involved, the company's current interaction with the patent office is limited to a single point of contact. The company must address the feedback from this 1 distinct examiner to resolve its 1 pending office action. This concentrated activity allows the company to focus its resources on a single regulatory challenge within the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRONZATI, GINA | 1 | 65.9% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683760 | Cell Transport and Storage Composition and Method | PRONZATI, GINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683760 | Cell Transport and Storage Composition and Method | PRONZATI, GINA | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18683760 | Cell Transport and Storage Composition and Method | PRONZATI, GINA | 1633 | §102§103§112 | Non-Final OA | — | Pending | Feb 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLife Science Group Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gina Pronzati has the most, with 1 of Life Science Group Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.